NervGen Pharma Corp. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NGEN Nasdaq 2830 nervgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NervGen Pharma Corp.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study - May 26th, 2026 5:15 am
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities - May 21st, 2026 9:27 pm
NervGen Announces Proposed Public Offering of Securities - May 21st, 2026 2:01 pm
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates - May 18th, 2026 5:15 am
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer - Apr 27th, 2026 5:30 am
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference - Apr 13th, 2026 5:45 am
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - Apr 7th, 2026 5:30 am
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates - Mar 31st, 2026 5:45 am
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Mar 12th, 2026 2:15 pm
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - Mar 4th, 2026 5:30 am
NervGen Pharma to Participate at Upcoming Investor Conferences - Feb 18th, 2026 5:30 am
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Feb 12th, 2026 2:15 pm
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - Feb 11th, 2026 5:00 am
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury - Feb 9th, 2026 5:00 am
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Feb 1st, 2026 5:56 am
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - Jan 20th, 2026 5:00 am